PTC Therapeutics, Inc. Net Income
PTC Therapeutics, Inc. (PTCT) reported Net Income of $83.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-07-30
- PTC Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was $83.50M.
- PTC Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$2.81M, a 100.32% decline year-over-year.
- PTC Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$134.61M.
- PTC Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was $15.90M.
- PTC Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2020 was -$438.16M.
- PTC Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2019 was -$251.58M.
- PTC Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2018 was -$128.08M.
- PTC Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2017 was -$79.00M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $83.50M 10-Q · filed 2026-07-30 | $80.69M 10-Q · filed 2026-07-30 | -$53.92M derived: sum of 3 quarters · filed 2026-07-30 | -$38.03M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | -$2.81M 10-Q · filed 2026-05-07 | -$137.42M derived: sum of 2 quarters · filed 2026-05-07 | -$121.52M derived: sum of 3 quarters · filed 2026-05-07 | -$186.37M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | -$134.61M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-20 | -$118.71M derived: sum of 2 quarters · filed 2026-04-20 | -$183.56M derived: sum of 3 quarters · filed 2026-07-30 | $683.00M DEF 14A · filed 2026-04-20 | $682.64M 10-K · filed 2026-02-19 | |||
| 2025-09-30 | $15.90M 10-Q · filed 2025-11-04 | -$48.95M derived: sum of 2 quarters · filed 2026-07-30 | $817.61M 10-Q · filed 2025-11-04 | $751.72M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | -$64.85M 10-Q · filed 2026-07-30 | $801.71M 10-Q · filed 2026-07-30 | $735.82M derived: sum of 3 quarters · filed 2026-07-30 | $629.17M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $866.56M 10-Q · filed 2026-05-07 | $800.67M derived: sum of 2 quarters · filed 2026-05-07 | $694.02M derived: sum of 3 quarters · filed 2026-05-07 | $594.84M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | -$65.89M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-20 | -$172.54M derived: sum of 2 quarters · filed 2026-04-20 | -$271.72M derived: sum of 3 quarters · filed 2026-04-20 | -$363.30M DEF 14A · filed 2026-04-20 | -$363.30M 10-K · filed 2025-02-27 | |||
| 2024-09-30 | -$106.65M 10-Q · filed 2025-11-04 | -$205.83M derived: sum of 2 quarters · filed 2025-11-04 | -$297.41M 10-Q · filed 2025-11-04 | -$453.20M derived: sum of 4 quarters · filed 2026-04-20 | ||||
| 2024-06-30 | -$99.18M 10-Q · filed 2025-08-07 | -$190.75M 10-Q · filed 2025-08-07 | -$346.54M derived: sum of 3 quarters · filed 2026-04-20 | -$479.51M derived: sum of 4 quarters · filed 2026-04-20 | ||||
| 2024-03-31 | -$91.58M 10-Q · filed 2025-05-06 | -$247.36M derived: sum of 2 quarters · filed 2026-04-20 | -$380.33M derived: sum of 3 quarters · filed 2026-04-20 | -$579.22M derived: sum of 4 quarters · filed 2026-04-20 | ||||
| 2023-12-31 | -$155.79M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-20 | -$288.76M derived: sum of 2 quarters · filed 2026-04-20 | -$487.64M derived: sum of 3 quarters · filed 2026-04-20 | -$626.60M DEF 14A · filed 2026-04-20 | -$626.60M 10-K · filed 2024-02-29 | |||
| 2023-09-30 | -$132.97M 10-Q · filed 2024-11-07 | -$331.85M derived: sum of 2 quarters · filed 2024-11-07 | -$470.81M 10-Q · filed 2024-11-07 | -$641.68M derived: sum of 4 quarters · filed 2026-04-20 | ||||
| 2023-06-30 | -$198.88M 10-Q · filed 2024-08-08 | -$337.84M 10-Q · filed 2024-08-08 | -$508.71M derived: sum of 3 quarters · filed 2026-04-20 | -$618.03M derived: sum of 4 quarters · filed 2026-04-20 | ||||
| 2023-03-31 | -$138.96M 10-Q · filed 2024-04-25 | -$309.83M derived: sum of 2 quarters · filed 2026-04-20 | -$419.15M derived: sum of 3 quarters · filed 2026-04-20 | -$571.23M derived: sum of 4 quarters · filed 2026-04-20 | ||||
| 2022-12-31 | -$170.87M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-20 | -$280.19M derived: sum of 2 quarters · filed 2026-04-20 | -$432.27M derived: sum of 3 quarters · filed 2026-04-20 | -$559.00M DEF 14A · filed 2026-04-20 | -$559.02M 10-K · filed 2023-02-21 | |||
| 2022-09-30 | -$109.31M 10-Q · filed 2023-10-26 | -$261.40M derived: sum of 2 quarters · filed 2023-10-26 | -$388.13M 10-Q · filed 2023-10-26 | -$531.39M derived: sum of 4 quarters · filed 2026-04-20 | ||||
| 2022-06-30 | -$152.09M 10-Q · filed 2023-08-03 | -$278.81M 10-Q · filed 2023-08-03 | -$422.08M derived: sum of 3 quarters · filed 2026-04-20 | -$555.70M derived: sum of 4 quarters · filed 2026-04-20 | ||||
| 2022-03-31 | -$126.73M 10-Q · filed 2023-04-27 | -$269.99M derived: sum of 2 quarters · filed 2026-04-20 | -$403.61M derived: sum of 3 quarters · filed 2026-04-20 | -$521.98M derived: sum of 4 quarters · filed 2026-04-20 | ||||
| 2021-12-31 | -$143.26M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-20 | -$276.89M derived: sum of 2 quarters · filed 2026-04-20 | -$395.26M derived: sum of 3 quarters · filed 2026-04-20 | -$523.90M DEF 14A · filed 2026-04-20 | -$523.90M 10-K · filed 2022-02-22 | |||
| 2021-09-30 | -$133.62M 10-Q · filed 2022-10-27 | -$251.99M derived: sum of 2 quarters · filed 2022-10-27 | -$380.64M 10-Q · filed 2022-10-27 | -$454.99M derived: sum of 4 quarters · filed 2022-10-27 | ||||
| 2021-06-30 | -$118.37M 10-Q · filed 2022-08-04 | -$247.01M 10-Q · filed 2022-08-04 | -$321.37M derived: sum of 3 quarters · filed 2022-08-04 | -$391.06M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | -$128.64M 10-Q · filed 2022-05-03 | -$203.00M derived: sum of 2 quarters · filed 2022-05-03 | -$272.69M derived: sum of 3 quarters · filed 2022-05-03 | -$454.12M derived: sum of 4 quarters · filed 2022-05-03 | ||||
| 2020-12-31 | -$74.35M 10-K · filed 2021-02-25 | -$144.05M derived: sum of 2 quarters · filed 2021-10-28 | -$325.47M derived: sum of 3 quarters · filed 2021-10-28 | -$438.16M 10-K · filed 2023-02-21 | ||||
| 2020-09-30 | -$69.69M 10-Q · filed 2021-10-28 | -$251.12M derived: sum of 2 quarters · filed 2021-10-28 | -$363.81M 10-Q · filed 2021-10-28 | -$441.48M derived: sum of 4 quarters · filed 2021-10-28 | ||||
| 2020-06-30 | -$181.43M 10-Q · filed 2021-07-29 | -$294.11M 10-Q · filed 2021-07-29 | -$371.79M derived: sum of 3 quarters · filed 2021-07-29 | -$431.79M derived: sum of 4 quarters · filed 2021-07-29 | ||||
| 2020-03-31 | -$112.69M 10-Q · filed 2021-05-04 | -$190.36M derived: sum of 2 quarters · filed 2021-05-04 | -$250.36M derived: sum of 3 quarters · filed 2021-05-04 | -$292.15M derived: sum of 4 quarters · filed 2021-05-04 | ||||
| 2019-12-31 | -$77.68M 10-K · filed 2021-02-25 | -$137.67M derived: sum of 2 quarters · filed 2021-02-25 | -$179.46M derived: sum of 3 quarters · filed 2021-02-25 | -$251.58M 10-K · filed 2022-02-22 | ||||
| 2019-09-30 | -$60.00M 10-K · filed 2021-02-25 | -$101.79M derived: sum of 2 quarters · filed 2021-02-25 | -$173.90M 10-Q · filed 2020-10-29 | -$222.23M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | -$41.79M 10-K · filed 2021-02-25 | -$113.90M 10-Q · filed 2020-08-05 | -$162.23M derived: sum of 3 quarters · filed 2021-02-25 | -$213.20M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | -$72.11M 10-K · filed 2021-02-25 | -$120.44M derived: sum of 2 quarters · filed 2021-02-25 | -$171.41M derived: sum of 3 quarters · filed 2021-02-25 | -$180.93M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | -$48.33M 10-K · filed 2020-03-02 | -$99.30M derived: sum of 2 quarters · filed 2020-03-02 | -$108.82M derived: sum of 3 quarters · filed 2020-03-02 | -$128.08M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | -$50.97M 10-K · filed 2020-03-02 | -$60.49M derived: sum of 2 quarters · filed 2020-03-02 | -$79.75M 10-Q · filed 2019-10-30 | -$78.48M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-06-30 | -$9.52M 10-K · filed 2020-03-02 | -$28.78M 10-Q · filed 2019-08-06 | -$27.51M derived: sum of 3 quarters · filed 2020-03-02 | -$61.25M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-03-31 | -$19.26M 10-K · filed 2020-03-02 | -$17.99M derived: sum of 2 quarters · filed 2020-03-02 | -$51.73M derived: sum of 3 quarters · filed 2020-03-02 | -$69.21M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2017-12-31 | $1.27M 10-K · filed 2019-03-01 | -$32.47M derived: sum of 2 quarters · filed 2019-03-01 | -$49.94M derived: sum of 3 quarters · filed 2019-03-01 | -$79.00M 10-K · filed 2020-03-02 | ||||
| 2017-09-30 | -$33.74M 10-K · filed 2019-03-01 | -$51.21M derived: sum of 2 quarters · filed 2019-03-01 | -$80.27M 10-Q · filed 2018-11-05 | -$107.07M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-06-30 | -$17.48M 10-K · filed 2019-03-01 | -$46.53M 10-Q · filed 2018-08-07 | -$73.33M derived: sum of 3 quarters · filed 2019-03-01 | -$108.50M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-03-31 | -$29.06M 10-K · filed 2019-03-01 | -$55.85M derived: sum of 2 quarters · filed 2019-03-01 | -$91.02M derived: sum of 3 quarters · filed 2019-03-01 | -$129.93M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2016-12-31 | -$26.80M 10-K · filed 2018-03-06 | -$61.96M derived: sum of 2 quarters · filed 2018-03-06 | -$100.88M derived: sum of 3 quarters · filed 2018-03-06 | -$142.11M 10-K · filed 2019-03-01 | ||||
| 2016-09-30 | -$35.17M 10-K · filed 2018-03-06 | -$74.08M derived: sum of 2 quarters · filed 2018-03-06 | -$115.31M 10-Q · filed 2017-11-02 | -$166.26M derived: sum of 4 quarters · filed 2018-03-06 | ||||
| 2016-06-30 | -$38.91M 10-K · filed 2018-03-06 | -$80.15M 10-Q · filed 2017-08-09 | -$131.09M derived: sum of 3 quarters · filed 2018-03-06 | -$174.32M derived: sum of 4 quarters · filed 2018-03-06 | ||||
| 2016-03-31 | -$41.23M 10-K · filed 2018-03-06 | -$92.18M derived: sum of 2 quarters · filed 2018-03-06 | -$135.40M derived: sum of 3 quarters · filed 2018-03-06 | -$173.76M derived: sum of 4 quarters · filed 2018-03-06 | ||||
| 2015-12-31 | -$50.95M 10-K · filed 2017-03-16 | -$94.17M derived: sum of 2 quarters · filed 2017-03-16 | -$132.53M derived: sum of 3 quarters · filed 2017-03-16 | -$170.45M 10-K · filed 2018-03-06 | ||||
| 2015-09-30 | -$43.22M 10-K · filed 2017-03-16 | -$81.58M derived: sum of 2 quarters · filed 2017-03-16 | -$119.50M 10-Q · filed 2016-11-03 | -$146.77M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-06-30 | -$38.36M 10-K · filed 2017-03-16 | -$76.28M 10-Q · filed 2016-08-04 | -$103.55M derived: sum of 3 quarters · filed 2017-03-16 | -$130.83M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-03-31 | -$37.91M 10-K · filed 2017-03-16 | -$65.18M derived: sum of 2 quarters · filed 2017-03-16 | -$92.47M derived: sum of 3 quarters · filed 2017-03-16 | -$117.57M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2014-12-31 | -$27.27M 10-K · filed 2016-02-29 | -$54.55M derived: sum of 2 quarters · filed 2016-02-29 | -$79.66M derived: sum of 3 quarters · filed 2016-02-29 | -$93.75M 10-K · filed 2017-03-16 | ||||
| 2014-09-30 | -$27.28M 10-K · filed 2016-02-29 | -$52.39M derived: sum of 2 quarters · filed 2016-02-29 | -$66.48M 10-Q · filed 2015-11-09 | -$84.37M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | -$25.10M 10-K · filed 2016-02-29 | -$39.20M 10-Q · filed 2015-07-31 | -$57.09M derived: sum of 3 quarters · filed 2016-02-29 | -$61.50M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | -$14.10M 10-K · filed 2016-02-29 | -$31.98M derived: sum of 2 quarters · filed 2016-02-29 | -$36.40M derived: sum of 3 quarters · filed 2016-02-29 | -$50.99M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | -$17.89M 10-K · filed 2015-03-02 | -$17.89M 10-K · filed 2014-03-06 | -$22.30M derived: sum of 2 quarters · filed 2015-03-02 | -$36.89M derived: sum of 3 quarters · filed 2015-03-02 | -$51.57M 10-K · filed 2016-02-29 | -$51.57M 10-K · filed 2014-03-06 | ||
| 2013-09-30 | -$4.42M 10-K · filed 2015-03-02 | -$4.42M 10-Q · filed 2013-11-14 | -$19.00M derived: sum of 2 quarters · filed 2015-03-02 | -$33.69M 10-Q · filed 2014-11-06 | -$33.69M 10-Q · filed 2013-11-14 | -$39.96M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-06-30 | -$14.59M 10-K · filed 2015-03-02 | -$14.59M 10-Q · filed 2013-08-13 | -$29.27M 10-Q · filed 2014-08-07 | -$29.27M 10-Q · filed 2013-08-13 | -$35.54M derived: sum of 3 quarters · filed 2015-03-02 | -$42.84M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-03-31 | -$14.69M 10-K · filed 2015-03-02 | -$14.68M 10-K · filed 2014-03-06 | -$20.96M derived: sum of 2 quarters · filed 2015-03-02 | -$28.25M derived: sum of 3 quarters · filed 2015-03-02 | -$34.32M derived: sum of 4 quarters · filed 2015-03-02 | |||
| 2012-12-31 | -$6.27M 10-K · filed 2014-03-06 | -$13.57M derived: sum of 2 quarters · filed 2014-03-06 | -$19.64M derived: sum of 3 quarters · filed 2014-03-06 | -$26.23M 10-K · filed 2015-03-02 | -$26.24M 10-K · filed 2014-03-06 | |||
| 2012-09-30 | -$7.30M 10-K · filed 2014-03-06 | -$13.37M derived: sum of 2 quarters · filed 2014-03-06 | -$19.96M 10-Q · filed 2013-11-14 | |||||
| 2012-06-30 | -$6.07M 10-K · filed 2014-03-06 | -$12.67M 10-Q · filed 2013-08-13 | ||||||
| 2012-03-31 | -$6.60M 10-K · filed 2014-03-06 | |||||||
| 2011-12-31 | $30.90M 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |